Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease

Brian Finan, Christoffer Clemmensen, Zhimeng Zhu, Kerstin Stemmer, Karine Gauthier, Luisa Mueller, Meri De Angelis, Kristin Moreth, Frauke Neff, Diego Perez-Tilve, Katrin Fischer, Dominik Lutter, Miguel A. Sanchez-Garrido, Peng Liu, Jan Tuckermann, Mohsen Malehmir, Marc E. Healy, Achim Weber, Mathias Heikenwalder, Martin JastrochMaximilian Kleinert, Sigrid Jall, Sara Brandt, Frederic Flamant, Karl-Werner Schramm, Heike Biebermann, Yvonne Doering, Christian Weber, Kirk M. Habegger, Michaela Keuper, Vasily Gelfanov, Fa Liu, Josef Koehrle, Jan Rozman, Helmut Fuchs, Valerie Gailus-Durner, Martin Hrabe de Angelis, Susanna M. Hofmann, Bin Yang, Matthias H. Tschoep*, Richard DiMarchi*, Timo D. Mueller

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease'. Together they form a unique fingerprint.

Keyphrases

INIS

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Chemistry